JUN 20, 2020 5:02 PM PDT

Antibodies Isolated From COVID-19 Patients Show Therapeutic Potential

WRITTEN BY: Carmen Leitch

Communities worldwide are emerging from lockdowns due to the SARS-CoV-2 pandemic virus, and it remains to be seen whether enough people will continue to wear masks, practice social-distancing, and take hygiene measures that are strong enough to stave off increases in infections. So far, the statistics in the United States are indicating that cases of the illness caused by the virus, COVID-19, will continue to increase.

Worldwide, over 400,000 people have died from COVID-19. Researchers have been searching for ways to reduce the death rate and find treatments for the infection. There is hope in dexamethasone, but it is only useful in severe cases and it does not work for every patient. A vaccine is also still a long way off.

A team of researchers is getting us closer to another treatment option - potent antibodies that have been found in the blood of people who recovered from COVID-19. These antibodies were found to protect cells growing in culture from the virus. The findings, which are paving the way to clinical trials that test these antibodies as preventive medications and treatments for active cases, have been reported in Science.

“The discovery of these very potent antibodies represents an extremely rapid response to a totally new pathogen,” said the study co-senior author Dennis Burton, Ph.D., the James and Jessie Minor Chair in Immunology in the Department of Immunology & Microbiology at Scripps Research.

It's possible that these antibodies could one day be administered to patients in the early phase of a COVID-19 infection so that severe disease is less likely, and virus levels are lowered. The antibodies could potentially be used as a kind of temporary vaccine, a prophylactic that could be given to those that may have been exposed, or who are at high risk, for example.

If antibodies that effectively neutralize the virus can be identified, it is likely that they could also be mass-produced and distributed for use once they're tested. This approach has helped in outbreaks of Ebola and respiratory syncytial virus.

“It has been a tremendous collaborative effort, and we’re now focused on making large quantities of these promising antibodies for clinical trials,” noted the study co-lead author Thomas Rogers, M.D., Ph.D., an adjunct assistant professor in the Department of Immunology & Microbiology at Scripps Research, and assistant professor of Medicine at UC San Diego. The research was quickly performed by teams at Scripps Research; IAVI, a nonprofit scientific research organization; and the University of California San Diego School of Medicine.

In this work, the researchers isolated antibodies from people that recovered from COVID-19 infections that ranged from mild to severe. They also created a test to determine whether cells that express a receptor that promotes viral infection, ACE2, were protected from infection by these antibodies. Over 1,000 antibody-producing cells were collected, and they were analyzed individually. Several blocked the virus in the cell culture model, and one was effective in a hamster model of heavy virus exposure.

“We leveraged our institution's decades of expertise in antibody isolation and quickly pivoted our focus to SARS-CoV-2 to identify these highly potent antibodies,” said study co-author Elise Landais, Ph.D., an IAVI principal scientist.

The researchers suggested that if safety tests go well, clinics may be able to try these antibodies in patients as soon as January.

Colorized scanning electron micrograph of an apoptotic cell (green) heavily infected with SARS-COV-2 virus particles (orange), isolated from a patient sample. Image at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. / Credit: NIAID

“We intend to make them available to those who need them most, including people in low- and middle-income countries,” Landais added.

The research also happened to reveal an antibody that can protect against SARS, which caused a viral outbreak in 2002. “That discovery gives us hope that we will eventually find broadly neutralizing antibodies that provide at least partial protection against all or most SARS coronaviruses, which should be useful if another one jumps to humans,” Burton said.

Another study has suggested that antibodies against the SARS-CoV-2 virus tend to be short-lived - though that does not mean immunity is. More research will also be needed to understand how immunity against this virus will work in different people.

Sources: Scripps Research, Science

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JUL 20, 2020
Genetics & Genomics
A Tiny But Efficient Cas Protein is Discovered in a Bacteriophage
JUL 20, 2020
A Tiny But Efficient Cas Protein is Discovered in a Bacteriophage
The microbes of the world are locked in a struggle for survival and a battle for resources. They compete directly in dif ...
JUL 27, 2020
Clinical & Molecular DX
Guidance for Optimization of a Real-Time qPCR Assay
JUL 27, 2020
Guidance for Optimization of a Real-Time qPCR Assay
Optimizing the formulation of reagents for your qPCR assay requires careful experimental design that looks across severa ...
JUL 26, 2020
Neuroscience
How COVID-19 Causes Loss of Smell
JUL 26, 2020
How COVID-19 Causes Loss of Smell
Temporary loss of smell, known as anosmia, is one of the most common early indicators of COVID-19. Although some say it ...
JUL 29, 2020
Genetics & Genomics
Droplets of DNA Can 'Boil' During an Enzymatic Interaction
JUL 29, 2020
Droplets of DNA Can 'Boil' During an Enzymatic Interaction
A phenomenon called liquid-liquid phase separation can be easily demonstrated by mixing oil and vinegar. It's not only f ...
SEP 01, 2020
Cardiology
Can the Protein Dysferlin Protect Your Heart from Reperfusion Injury
SEP 01, 2020
Can the Protein Dysferlin Protect Your Heart from Reperfusion Injury
Have you ever experienced the head rush you get from standing up to fast? Well, oddly enough, something similar happens ...
SEP 03, 2020
Cell & Molecular Biology
Diagnosing Non-Celiac Gluten Sensitivity
SEP 03, 2020
Diagnosing Non-Celiac Gluten Sensitivity
Many clinicians once thought that only celiac disease caused gluten intolerance. But some people without it report gastr ...
Loading Comments...